0001209191-17-047729.txt : 20170804 0001209191-17-047729.hdr.sgml : 20170804 20170804164820 ACCESSION NUMBER: 0001209191-17-047729 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170802 FILED AS OF DATE: 20170804 DATE AS OF CHANGE: 20170804 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH IAN F CENTRAL INDEX KEY: 0001197032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 171009203 MAIL ADDRESS: STREET 1: C/O ACORDA THERAPEUTICS, INC. STREET 2: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-08-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001197032 SMITH IAN F C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, CFO & COO Common Stock 2017-08-02 4 M 0 2155 91.05 A 118043 D Common Stock 2017-08-02 4 S 0 500 152.49 D 117543 D Common Stock 2017-08-02 4 S 0 500 153.57 D 117043 D Common Stock 2017-08-02 4 S 0 700 154.55 D 116343 D Common Stock 2017-08-02 4 S 0 455 156.09 D 115888 D Common Stock 5306 I 401(k) Stock Option (Right to Buy) 91.05 2017-08-02 4 M 0 2155 0.00 D 2026-02-01 Common Stock 2155 21552 D Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $152.49 (range $152.00 to $152.76). Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $153.57 (range $153.08 to $154.05). Open market sales reported on this line occurred at a weighted average price of $154.55 (range $154.20 to $154.93). Open market sales reported on this line occurred at a weighted average price of $156.09 (range $155.49 to $156.40). The option vests in 16 quarterly installments from 2/2/2016. /s/ Omar White, Attorney-in-Fact 2017-08-04